Gastric cancer immunotherapy prediction model
Part of Cancer, Digestive system clinical trials.
This study looks at markers in your tumor to predict how well immunotherapy might work for you. It aims to create a model that helps doctors choose the best treatment for advanced gastric cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced or metastatic gastric or gastroesophageal junction cancer that cannot be removed with surgery.
- You are between 18 and 75 years old.
- You are scheduled to receive immunotherapy combined with chemotherapy as your first treatment, with or without anti-HER2 therapy.
- You have at least one tumor that can be measured on scans and you are still able to care for yourself (ECOG score 0-2).
- You have not had any other cancer in the past 3 years, except possibly certain skin cancers.
- You do not have any other serious medical conditions that would make the study risky for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether blood tests before treatment can predict side effects from immunotherapy (PD-1/PD-L1 inhibitors) in people with gastric cancer. If you are about to start this type of treatment, your participation could help doctors manage side effects better.
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
This trial tests two immunotherapy drugs given before surgery for locally advanced gastric cancer that has a specific genetic marker (MSI-H or dMMR). The goal is to shrink the tumor and improve outcomes before removing it surgically.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs before surgery for people with resectable gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This study checks blood and tissue biomarkers in people with advanced gastric cancer that has spread to the lining of the abdomen. It looks at patients who have already had HIPEC plus a PD-1/PD-L1 antibody treatment, to better understand response and eligibility.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.